Matches in SemOpenAlex for { <https://semopenalex.org/work/W2775008688> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2775008688 abstract "Purpose This phase-III, randomised, double-blind, active-controlled, non-inferiority study aimed to demonstrate the efficacy and safety of once-daily (QD) ESL as monotherapy treatment for newly diagnosed adults with POS in comparison to twice-daily (BID) controlled-release carbamazepine (CBZ-CR). Method Patients (≥18 years) were randomised (1:1) to receive ESL or CBZ-CR in a 3-step dose-level design. Each dose-level was maintained through a 26 week Evaluation-Period (EP). Subjects who remained seizure-free at any dose-level continued through subsequent periods/phases. Primary-endpoint was proportion of patients with 26 week seizure freedom in the per-protocol (PP) population. Results 815 patients were randomised (PP population; ESL n=388; CBZ-CR n=397). In the PP population, the proportion of subjects classified as seizure-free for the entire 26 week Evaluation Period at the last evaluated dose was comparable between the ESL group (71.1%) and the CBZ-CR group (75.6%) and ESL was shown to be non-inferior to CBZ-CR. Results from the sensitivity analyses were consistent with the primary analysis results. ESL was non-inferior to CBZ-CR during 1 year of treatment, as the 1 year seizure-free rate at the last evaluated dose (PP population) was 64.7% on ESL group and 70.3% on CBZ-CR group. Conclusion ESL QD was non-inferior to CBZ-CR BID for seizure freedom rates in patients with newly diagnosed epilepsy. Sponsored by BIAL-Portela and Ca S.A." @default.
- W2775008688 created "2017-12-22" @default.
- W2775008688 creator A5000447612 @default.
- W2775008688 creator A5016038115 @default.
- W2775008688 creator A5020135618 @default.
- W2775008688 creator A5020213111 @default.
- W2775008688 creator A5031300189 @default.
- W2775008688 creator A5061406453 @default.
- W2775008688 creator A5061862920 @default.
- W2775008688 creator A5076045134 @default.
- W2775008688 creator A5078712323 @default.
- W2775008688 creator A5080676838 @default.
- W2775008688 date "2017-12-01" @default.
- W2775008688 modified "2023-10-08" @default.
- W2775008688 title "PO043 Efficacy of eslicarbazepine acetate versus controlled-release carbamazepine as monotherapy in patients with newly diagnosed partial-onset seizures" @default.
- W2775008688 doi "https://doi.org/10.1136/jnnp-2017-abn.76" @default.
- W2775008688 hasPublicationYear "2017" @default.
- W2775008688 type Work @default.
- W2775008688 sameAs 2775008688 @default.
- W2775008688 citedByCount "0" @default.
- W2775008688 crossrefType "journal-article" @default.
- W2775008688 hasAuthorship W2775008688A5000447612 @default.
- W2775008688 hasAuthorship W2775008688A5016038115 @default.
- W2775008688 hasAuthorship W2775008688A5020135618 @default.
- W2775008688 hasAuthorship W2775008688A5020213111 @default.
- W2775008688 hasAuthorship W2775008688A5031300189 @default.
- W2775008688 hasAuthorship W2775008688A5061406453 @default.
- W2775008688 hasAuthorship W2775008688A5061862920 @default.
- W2775008688 hasAuthorship W2775008688A5076045134 @default.
- W2775008688 hasAuthorship W2775008688A5078712323 @default.
- W2775008688 hasAuthorship W2775008688A5080676838 @default.
- W2775008688 hasConcept C118552586 @default.
- W2775008688 hasConcept C126322002 @default.
- W2775008688 hasConcept C168563851 @default.
- W2775008688 hasConcept C187212893 @default.
- W2775008688 hasConcept C203092338 @default.
- W2775008688 hasConcept C2778186239 @default.
- W2775008688 hasConcept C2779253243 @default.
- W2775008688 hasConcept C2908647359 @default.
- W2775008688 hasConcept C42219234 @default.
- W2775008688 hasConcept C71924100 @default.
- W2775008688 hasConcept C99454951 @default.
- W2775008688 hasConceptScore W2775008688C118552586 @default.
- W2775008688 hasConceptScore W2775008688C126322002 @default.
- W2775008688 hasConceptScore W2775008688C168563851 @default.
- W2775008688 hasConceptScore W2775008688C187212893 @default.
- W2775008688 hasConceptScore W2775008688C203092338 @default.
- W2775008688 hasConceptScore W2775008688C2778186239 @default.
- W2775008688 hasConceptScore W2775008688C2779253243 @default.
- W2775008688 hasConceptScore W2775008688C2908647359 @default.
- W2775008688 hasConceptScore W2775008688C42219234 @default.
- W2775008688 hasConceptScore W2775008688C71924100 @default.
- W2775008688 hasConceptScore W2775008688C99454951 @default.
- W2775008688 hasLocation W27750086881 @default.
- W2775008688 hasOpenAccess W2775008688 @default.
- W2775008688 hasPrimaryLocation W27750086881 @default.
- W2775008688 hasRelatedWork W1179933929 @default.
- W2775008688 hasRelatedWork W1546717111 @default.
- W2775008688 hasRelatedWork W1980087402 @default.
- W2775008688 hasRelatedWork W1984234523 @default.
- W2775008688 hasRelatedWork W2012147943 @default.
- W2775008688 hasRelatedWork W2045654908 @default.
- W2775008688 hasRelatedWork W2045880997 @default.
- W2775008688 hasRelatedWork W2051013481 @default.
- W2775008688 hasRelatedWork W2053887797 @default.
- W2775008688 hasRelatedWork W2082455791 @default.
- W2775008688 hasRelatedWork W2168143783 @default.
- W2775008688 hasRelatedWork W2354922624 @default.
- W2775008688 hasRelatedWork W2375913945 @default.
- W2775008688 hasRelatedWork W2380697014 @default.
- W2775008688 hasRelatedWork W2383195729 @default.
- W2775008688 hasRelatedWork W2468359622 @default.
- W2775008688 hasRelatedWork W2473448478 @default.
- W2775008688 hasRelatedWork W2550267293 @default.
- W2775008688 hasRelatedWork W2984387616 @default.
- W2775008688 hasRelatedWork W3028741087 @default.
- W2775008688 isParatext "false" @default.
- W2775008688 isRetracted "false" @default.
- W2775008688 magId "2775008688" @default.
- W2775008688 workType "article" @default.